PUBLISHER: The Business Research Company | PRODUCT CODE: 1957847
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957847
Targeted Alpha-Therapy Global Market Report 2026
Targeted alpha-therapy (TAT) is a type of radiation treatment that administers highly potent alpha-particle-emitting isotopes directly to cancer cells or diseased tissues. The therapy employs targeting molecules, such as antibodies, peptides, or small molecules, which bind specifically to cancer cell markers, enabling the alpha particles to induce lethal double-strand DNA breaks in nearby cells while reducing damage to surrounding healthy tissue.
The main isotope types of targeted alpha therapy include actinium-225, radium-223, lead-212, bismuth-213, and others. Actinium-225 is a highly potent alpha-emitting radioisotope commonly used in targeted therapies because of its suitable half-life and decay characteristics. This therapy is utilized for conditions such as prostate cancer, bone metastases, pancreatic cancer, and others, with end-users including hospitals, cancer research institutes, specialty clinics, lymphoma centers, and others.
Tariffs are influencing the targeted alpha-therapy market by increasing costs of imported radioisotopes, nuclear production equipment, shielding materials, and precision delivery systems. North America and Europe are most affected due to dependence on specialized isotope supply chains, while Asia-Pacific faces higher costs in isotope production and export logistics. These tariffs are increasing treatment development costs and limiting isotope availability timelines. However, they are also encouraging domestic isotope production, regional nuclear infrastructure investment, and long-term supply chain stabilization for alpha-therapy development.
The targeted alpha-therapy market research report is one of a series of new reports from The Business Research Company that provides targeted alpha-therapy market statistics, including targeted alpha-therapy industry global market size, regional shares, competitors with a targeted alpha-therapy market share, detailed targeted alpha-therapy market segments, market trends and opportunities, and any further data you may need to thrive in the targeted alpha-therapy industry. This targeted alpha-therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The targeted alpha-therapy market size has grown rapidly in recent years. It will grow from $1.03 billion in 2025 to $1.2 billion in 2026 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to advances in nuclear medicine research, increasing unmet needs in advanced cancers, expansion of radiopharmaceutical clinical trials, availability of medical isotopes, growth in targeted radiation therapy adoption.
The targeted alpha-therapy market size is expected to see rapid growth in the next few years. It will grow to $2.25 billion in 2030 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to increasing investment in isotope manufacturing infrastructure, rising adoption of personalized radiotherapy, expansion of targeted alpha therapies into new indications, growing regulatory support for radiopharmaceuticals, increasing collaboration between nuclear and oncology specialists. Major trends in the forecast period include increasing development of alpha-emitting radiopharmaceuticals, rising use of targeted radioligand therapies, growing focus on precision radiation delivery, expansion of isotope production capabilities, enhanced integration of targeting molecules.
The increasing emphasis on precision medicine is expected to drive the growth of the targeted alpha-therapy market in the coming years. Precision medicine is a healthcare approach that tailors prevention, diagnosis, and treatment according to an individual's genetic makeup, lifestyle, and environment to achieve more effective outcomes. The adoption of precision medicine is rising due to the expanding availability of genetic testing, which allows for more accurate diagnoses and targeted therapies with better patient results. Targeted alpha-therapy supports precision medicine by delivering highly potent alpha-emitting isotopes directly to cancer cells, providing personalized and precise treatment while reducing harm to healthy tissues. For example, in March 2024, the American Pharmaceutical Review, a US-based journal, reported that global spending on precision medicine treatments was nearly $32 billion in 2022 and is expected to surpass $124 billion by 2027. Consequently, the growing emphasis on precision medicine is fueling the expansion of the targeted alpha-therapy market.
Major companies operating in the targeted alpha-therapy market are concentrating on developing innovative approaches such as peptide receptor radionuclide therapy to enhance the efficacy of targeted cancer treatments, reduce off-target effects, and improve patient outcomes. Peptide receptor radionuclide therapy (PRRT) is a targeted cancer treatment that delivers radioactive isotopes directly to tumor cells by attaching them to peptides that specifically bind to receptors overexpressed on cancer cells, thereby limiting damage to healthy tissue. For example, in February 2024, RadioMedix Inc., a US-based biotechnology company, collaborated with Orano Med, a US-based pharmaceutical company, and received FDA breakthrough device designation for the first targeted alpha therapy, AlphaMedix (lead-212-Dotamtate), aimed at treating neuroendocrine tumors. It is designed to treat advanced gastroenteropancreatic neuroendocrine tumors by delivering highly potent alpha radiation directly to cancer cells while sparing healthy tissue. Its primary advantage lies in the high energy and short path length of alpha particles, which induce lethal DNA damage to tumor cells with minimal toxicity. This therapy provides a promising option for patients who are treatment-naive or have limited response to current beta-emitter therapies, aiming to improve efficacy and safety in hard-to-treat neuroendocrine tumors.
In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to enhance cancer treatment and patient outcomes by developing more precise, targeted next-generation radioconjugate therapies to replace traditional chemotherapy and radiotherapy. Fusion Pharmaceuticals Inc. is a Canada-based biotech company specializing in targeted alpha-therapy.
Major companies operating in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.
North America was the largest region in the targeted alpha-therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the targeted alpha-therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the targeted alpha-therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The targeted alpha-therapy market consists of sales of neptunium-225 thorium-227 and astatine-211. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Targeted Alpha-Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses targeted alpha-therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for targeted alpha-therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The targeted alpha-therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
- Markets Covered:1) By Isotope Type: Actinium-225; Radium-223; Lead-212; Bismuth-213; Other Isotype Types
- 2) By Application: Prostate Cancer; Bone Metastases; Pancreatic Cancer; Other Applications
- 3) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics; Lymphoma; Other End Users
- Subsegments:
- 1) By Actinium-225: Ac-225 Lintuzumab; Ac-225 PSMA-617; Ac-225 DOTATATE
- 2) By Radium-223: Radium-223 Dichloride (Xofigo)
- 3) By Lead-212: Pb-212 DOTAMTATE (AlphaMedix); Pb-212 TCMC-Trastuzumab
- 4) By Bismuth-213: Bi-213 Lintuzumab; Bi-213 DOTATOC
- 5) By Other Isotope Types: Thorium-227; Astatine-211; Terbium-149
- Companies Mentioned: Bayer Aktiengesellschaft; Novartis AG; Lantheus Holdings Inc.; Telix Pharmaceuticals Limited; Eckert & Ziegler Strahlen- und Medizintechnik AG; Actinium Pharmaceuticals Inc.; RayzeBio Inc.; ITM Isotope Technologies Munich SE; ARTBIO Inc.; AdvanCell Pty Ltd.; IONETIX Corporation; Abdera Therapeutics Inc.; Aktis Oncology Inc.; Alpha-9 Oncology Inc.; Clarity Pharmaceuticals Pty Ltd.; Nucleus RadioPharma; Oncoinvent AS; PanTera; Perspective Therapeutics Inc.; RadioMedix Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: Word, PDF or Interactive Report
- + Excel Dashboard
- Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
Table of Contents
1. Executive Summary
- 1.1. Key Market Insights (2020-2035)
- 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
- 1.3. Major Factors Driving the Market
- 1.4. Top Three Trends Shaping the Market
2. Targeted Alpha-Therapy Market Characteristics
- 2.1. Market Definition & Scope
- 2.2. Market Segmentations
- 2.3. Overview of Key Products and Services
- 2.4. Global Targeted Alpha-Therapy Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
- Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
- 2.4.4. Market Attractiveness Scoring and Interpretation
- 2.4.5. Strategic Implications and Recommendations
3. Targeted Alpha-Therapy Market Supply Chain Analysis
- 3.1. Overview of the Supply Chain and Ecosystem
- 3.2. List Of Key Raw Materials, Resources & Suppliers
- 3.3. List Of Major Distributors and Channel Partners
- 3.4. List Of Major End Users
4. Global Targeted Alpha-Therapy Market Trends And Strategies
- 4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
- 4.2. Major Trends
- 4.2.1 Increasing Development Of Alpha-Emitting Radiopharmaceuticals
- 4.2.2 Rising Use Of Targeted Radioligand Therapies
- 4.2.3 Growing Focus On Precision Radiation Delivery
- 4.2.4 Expansion Of Isotope Production Capabilities
- 4.2.5 Enhanced Integration Of Targeting Molecules
5. Targeted Alpha-Therapy Market Analysis Of End Use Industries
- 5.1 Hospitals
- 5.2 Cancer Research Institutes
- 5.3 Specialty Clinics
- 5.4 Nuclear Medicine Centers
- 5.5 Oncology Treatment Centers
6. Targeted Alpha-Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Targeted Alpha-Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
- 7.1. Global Targeted Alpha-Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 7.2. Global Targeted Alpha-Therapy Market Size, Comparisons And Growth Rate Analysis
- 7.3. Global Targeted Alpha-Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
- 7.4. Global Targeted Alpha-Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Targeted Alpha-Therapy Total Addressable Market (TAM) Analysis for the Market
- 8.1. Definition and Scope of Total Addressable Market (TAM)
- 8.2. Methodology and Assumptions
- 8.3. Global Total Addressable Market (TAM) Estimation
- 8.4. TAM vs. Current Market Size Analysis
- 8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Targeted Alpha-Therapy Market Segmentation
- 9.1. Global Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Actinium-225, Radium-223, Lead-212, Bismuth-213, Other Isotype Types
- 9.2. Global Targeted Alpha-Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Prostate Cancer, Bone Metastases, Pancreatic Cancer, Other Applications
- 9.3. Global Targeted Alpha-Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Hospitals, Cancer Research Institutes, Specialty Clinics, Lymphoma, Other End Users
- 9.4. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Actinium-225, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Ac-225 Lintuzumab, Ac-225 PSMA-617, Ac-225 DOTATATE
- 9.5. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Radium-223, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Radium-223 Dichloride (Xofigo)
- 9.6. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Lead-212, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Pb-212 DOTAMTATE (AlphaMedix), Pb-212 TCMC-Trastuzumab
- 9.7. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Bismuth-213, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Bi-213 Lintuzumab, Bi-213 DOTATOC
- 9.8. Global Targeted Alpha-Therapy Market, Sub-Segmentation Of Other Isotope Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- Thorium-227, Astatine-211, Terbium-149
10. Targeted Alpha-Therapy Market Regional And Country Analysis
- 10.1. Global Targeted Alpha-Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
- 10.2. Global Targeted Alpha-Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Targeted Alpha-Therapy Market
- 11.1. Asia-Pacific Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Targeted Alpha-Therapy Market
- 12.1. China Targeted Alpha-Therapy Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 12.2. China Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Targeted Alpha-Therapy Market
- 13.1. India Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Targeted Alpha-Therapy Market
- 14.1. Japan Targeted Alpha-Therapy Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 14.2. Japan Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Targeted Alpha-Therapy Market
- 15.1. Australia Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Targeted Alpha-Therapy Market
- 16.1. Indonesia Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Targeted Alpha-Therapy Market
- 17.1. South Korea Targeted Alpha-Therapy Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 17.2. South Korea Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Targeted Alpha-Therapy Market
- 18.1. Taiwan Targeted Alpha-Therapy Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 18.2. Taiwan Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Targeted Alpha-Therapy Market
- 19.1. South East Asia Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 19.2. South East Asia Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Targeted Alpha-Therapy Market
- 20.1. Western Europe Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 20.2. Western Europe Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Targeted Alpha-Therapy Market
- 21.1. UK Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Targeted Alpha-Therapy Market
- 22.1. Germany Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Targeted Alpha-Therapy Market
- 23.1. France Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Targeted Alpha-Therapy Market
- 24.1. Italy Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Targeted Alpha-Therapy Market
- 25.1. Spain Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Targeted Alpha-Therapy Market
- 26.1. Eastern Europe Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 26.2. Eastern Europe Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Targeted Alpha-Therapy Market
- 27.1. Russia Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Targeted Alpha-Therapy Market
- 28.1. North America Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 28.2. North America Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Targeted Alpha-Therapy Market
- 29.1. USA Targeted Alpha-Therapy Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 29.2. USA Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Targeted Alpha-Therapy Market
- 30.1. Canada Targeted Alpha-Therapy Market Overview
- Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 30.2. Canada Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Targeted Alpha-Therapy Market
- 31.1. South America Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 31.2. South America Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Targeted Alpha-Therapy Market
- 32.1. Brazil Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Targeted Alpha-Therapy Market
- 33.1. Middle East Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 33.2. Middle East Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Targeted Alpha-Therapy Market
- 34.1. Africa Targeted Alpha-Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 34.2. Africa Targeted Alpha-Therapy Market, Segmentation By Isotope Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Targeted Alpha-Therapy Market Regulatory and Investment Landscape
36. Targeted Alpha-Therapy Market Competitive Landscape And Company Profiles
- 36.1. Targeted Alpha-Therapy Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
- 36.2. Targeted Alpha-Therapy Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
- 36.3. Targeted Alpha-Therapy Market Company Profiles
- 36.3.1. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Telix Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Eckert & Ziegler Strahlen- und Medizintechnik AG Overview, Products and Services, Strategy and Financial Analysis
37. Targeted Alpha-Therapy Market Other Major And Innovative Companies
- Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.
38. Global Targeted Alpha-Therapy Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Targeted Alpha-Therapy Market
40. Targeted Alpha-Therapy Market High Potential Countries, Segments and Strategies
- 40.1 Targeted Alpha-Therapy Market In 2030 - Countries Offering Most New Opportunities
- 40.2 Targeted Alpha-Therapy Market In 2030 - Segments Offering Most New Opportunities
- 40.3 Targeted Alpha-Therapy Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies
41. Appendix
- 41.1. Abbreviations
- 41.2. Currencies
- 41.3. Historic And Forecast Inflation Rates
- 41.4. Research Inquiries
- 41.5. The Business Research Company
- 41.6. Copyright And Disclaimer
